The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | What can clinicians do to address the impact of transfusion-dependent thalassemia on patients’ QoL?
Farrukh Shah, MBBS, FRCP, FRCPath, MD, University College London Hospitals, London, UK, outlines the impact that transfusion-dependent beta-thalassemia major has on the quality of life of patients and highlights how clinicians can tailor treatment to prevent complications, reduce symptom burden, and improve patient quality of life (QoL). This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Haemoglobinopathy work: National Haemoglobinopathy Registry (NHR); Advisory board: Bristol Myers Squibb, Novartis, Vertex; Lecture Fees: Bristol Myers Squibb, Novartis, Chesi, Vertex; Safety Monitoring Committee: Agios, Pharmacosmos.
